

DEERFIELD, IL 60015

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F	ILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/526,357	03/16/2000		Lecon Woo	1417Y P 415	2552
29200	7590	01/05/2005		EXAM	INER
BAXTER HEALTHCARE CORPORATION				MULLIS, JEFFREY C	
RENAL DIV	/ISION				DADED MARINED
1 BAXTER PARKWAY				ART UNIT	PAPER NUMBER
DF3-3E				1711	

DATE MAILED: 01/05/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
055	09/526,357	WOO ET AL.
Office Action Summary	Examiner	Art Unit
	Jeffrey C. Mullis	1711
The MAILING DATE of this communication apperiod for Reply	pears on the cover sheet v	vith the correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a sly within the statutory minimum of th will apply and will expire SIX (6) MC e, cause the application to become A	reply be timely filed irty (30) days will be considered timely. NTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).
Status		
1)⊠ Responsive to communication(s) filed on 09 D	December 2004	
	s action is non-final.	
3) Since this application is in condition for allowa		tters, prosecution as to the merits is
closed in accordance with the practice under		
Disposition of Claims		
4) ⊠ Claim(s) <u>1-8,13-27,32-42,47-61,66-76,81-95 a</u> 4a) Of the above claim(s) is/are withdra 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) <u>1-8,13-27,32-42,47-61,66-76,81-95 a</u> 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	wn from consideration.  and 100-103 is/are rejecte	
Application Papers		
9) The specification is objected to by the Examine	er.	
10) The drawing(s) filed on is/are: a) acc		by the Examiner.
Applicant may not request that any objection to the		
Replacement drawing sheet(s) including the correct		
11) The oath or declaration is objected to by the Ex	xaminer. Note the attache	d Office Action or form PTO-152.
Priority under 35 U.S.C. § 119		
<ul> <li>12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:</li> <li>1. Certified copies of the priority document</li> <li>2. Certified copies of the priority document</li> <li>3. Copies of the certified copies of the priority application from the International Bureau</li> <li>* See the attached detailed Office action for a list</li> </ul>	ts have been received. ts have been received in <i>i</i> rity documents have beer u (PCT Rule 17.2(a)).	Application No  n received in this National Stage
Attachment(s)		
1) Notice of References Cited (PTO-892)		Summary (PTO-413)
Notice of Draftsperson's Patent Drawing Review (PTO-948)     Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)     Paper No(s)/Mail Date	Paper No. 5) Notice of 6) Other:	s)/Mail Date Informal Patent Application (PTO-152)

ところである。 とればいない かっけんり こうばんせんし しょくちょう

Application/Control Number: 09/526,357

Art Unit: 1711

All previous rejections have been withdrawn in view of applicants' amendment and remarks.

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-8, 13-27, 32-42, 47-61, 66-76, 81-95 and 100-103 rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-58 are of U.S. Patent No. 6,743,523. Although the conflicting claims are not identical, they are not patentably distinct from each other because the materials of the instant claims encompass those of the patent. Note that claims 19 and 22 of the patent specifically disclose applicants characteristics and radiation treatment and that the patent and application specification disclose that such treatment can be used to produce materials having applicants' characteristics.

Any inquiry concerning this communication should be directed to Jeffrey C. Mullis at telephone number 703 308 2820.

Art Unit: 1711

Jeffrey C. Mullis J Mullis Art Unit 1711